APOE and Alzheimer disease: Several studies have previously suggested that mApoE-PA-LIPs could potentially be advantageously used with regard to AD as they proved to reduce the Aβ burden in mouse animal models of the disease and to prevent memory impairment in a model of presymptomatic stage of AD.6,7 This capability is likely attributable to the presence, on their surface, of PA molecules conferring the ability to bind Aβ with high affinity2 and of the peptide containing the receptor-binding sequence of ApoE, improving their transport through the BBB.13